GLP-1-Fc Fusion Protein Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The stability of GLP-1-Fc fusion protein solutions is compromised by the formation of soluble aggregates and insoluble particles during long-term storage, which affects their physical and chemical stability, especially when stored in vials rather than syringes.
Innovation Solution
A solution formulation comprising 0.5 to 10 mg/mL of GLP-1-Fc fusion protein, 5 to 20 mM citrate buffer, 0.01 to 0.05% polysorbate-80, and 4.0 to 5.3% mannitol, with a pH of 6-7, is developed to enhance stability and minimize aggregate formation, with polysorbate-80 and mannitol concentrations specifically optimized to prevent particle formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If a GLP-1-Fc fusion protein is formulated in a solution for long-term storage, then the therapeutic availability is improved, but soluble aggregates and insoluble particles form during storage
Solution Approach 1:
Polysorbate-80 is introduced as an intermediary surfactant that adsorbs to the surface of the GLP-1-Fc fusion protein and excipients, preventing direct protein-protein interactions that lead to aggregation. The surfactant forms a protective layer around protein molecules, maintaining their solubility and preventing particle formation during long-term storage.
Solution Approach 2:
The formulation optimizes multiple parameters including pH (adjusted to 6.0-7.5 using citrate or phosphate buffers), ionic strength, and excipient concentrations. Mannitol is added as a stabilizing excipient at specific concentrations to prevent aggregation. These parameter changes create an optimal environment that maintains protein solubility and prevents aggregate formation over time.
2Quantity of substance
If the concentration of GLP-1-Fc fusion protein is increased to reduce dosing volume, then the therapeutic efficacy is improved, but the formation of aggregates and particles increases
Solution Approach 1:
Polysorbate-80 acts as a protective intermediary that becomes increasingly important at higher protein concentrations. The surfactant prevents the close proximity interactions between protein molecules that would otherwise lead to aggregation, enabling the formulation to maintain homogeneity even at elevated protein concentrations.
Solution Approach 2:
The formulation creates a composite system combining GLP-1-Fc fusion protein with multiple excipients (polysorbate-80, mannitol, citrate/phosphate buffers) that work synergistically. This composite formulation maintains solution homogeneity at higher protein concentrations by distributing stress and preventing protein-protein interactions through the combined protective effects of all components.
3Duration of action of stationary object
If the formulation is stored in vials for long-term stability, then the storage duration is extended, but physical instability and particle formation increase compared to syringe storage
Solution Approach 1:
Polysorbate-80 serves as a protective intermediary that is particularly crucial during vial storage. The surfactant continuously adsorbs to protein surfaces and prevents aggregation that is more likely to occur in vials due to larger headspace, potential temperature fluctuations, and longer storage durations compared to syringe storage.
Solution Approach 2:
The formulation parameters are specifically optimized for long-term vial storage conditions, including buffer composition and excipient concentrations that maintain pH stability and prevent aggregation over extended periods. The citrate or phosphate buffer system maintains optimal pH while mannitol provides structural stabilization during long-term storage in vials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly reduces the formation of soluble and insoluble particles, maintaining stability over long-term storage and showing improved stability in syringes compared to vials, ensuring the biological activity and therapeutic efficacy of the GLP-1-Fc fusion protein.
Implementation Method 1
0.01 to 0.05% (w/v) polysorbate-80
Implementation Method 2
4.0 to 5.3% (w/v) mannitol
Implementation Method 3
5 to 20 mM citrate buffer, and having a pH of 6-7
Data Source
AI summary
The invention provides a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein at about pH 6.5 in citrate buffer with polysorbate-80 and mannitol. The formulation is useful in treating diabetes and obesity as well as a variety of other conditions or disorders.